• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Viral Immunol . A Seroprevalence Study on Residents in a Senior Care Facility with Breakthrough SARS-CoV-2 Omicron Infection

tetano

Editor, Senior Moderator
Viral Immunol


. 2023 Mar 23.
doi: 10.1089/vim.2022.0133. Online ahead of print.
A Seroprevalence Study on Residents in a Senior Care Facility with Breakthrough SARS-CoV-2 Omicron Infection


Heui Man Kim[SUP] 1 [/SUP], Eun Ju Lee[SUP] 1 [/SUP], Sang Won O[SUP] 1 [/SUP], Yong Jun Choi[SUP] 1 [/SUP], Hyeokjin Lee[SUP] 1 [/SUP], Sae Jin Oh[SUP] 1 [/SUP], Jeong-Min Kim[SUP] 1 [/SUP], Ae Kyung Park[SUP] 1 [/SUP], Jeong-Ah Kim[SUP] 1 [/SUP], Chae Young Lee[SUP] 1 [/SUP], Jong Mu Kim[SUP] 2 [/SUP], Hanul Park[SUP] 2 [/SUP], Young Joon Park[SUP] 2 [/SUP], Jeong-Hee Yu[SUP] 3 [/SUP], Eun-Young Kim[SUP] 3 [/SUP], Hwa-Pyeong Ko[SUP] 4 [/SUP], Eun-Jin Kim[SUP] 1 [/SUP]



Affiliations

Abstract

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began spreading rapidly in the community in November 2021, becoming the dominant variant in the Republic of Korea in 2022. Although its pathogenesis in healthy individuals was low, the severity and hospitalization rate was higher in the elderly and immunocompromised patients. We aimed to investigate the immunogenicity in acute and convalescent phases of breakthrough infection by Omicron in elderly individuals. Serological data were assessed by electrochemiluminescence immunoassay, enzyme-linked immunosorbent assay, and plaque-reduction neutralization tests. SARS-CoV-2-specific antibody and immunoglobulin G levels in the acute phase were higher in third dose-vaccinated elderly than in first and second dose-vaccinated patients. The neutralization antibody titer was detected only in third dose-vaccinated patients, and the titer was higher for the Delta than the Omicron variant. In the convalescent phase of Omicron infection, the neutralization antibody titer of vaccinated patients was higher for the Delta than the Omicron variant except in unvaccinated individuals. We demonstrated that the cause of the vulnerability to Omicron variant infection in third dose-vaccinated elderly was due to the low neutralization antibody level against Omicron. A fourth dose of vaccination is required in the elderly to reduce hospitalization and mortality caused by the Omicron variant.

Keywords: COVID-19 vaccination; Omicron variant; SARS-CoV-2; breakthrough infection; elderly individuals; neutralizing antibody.
 
Back
Top Bottom